This pathway activation produces: Glucose-dependent insulin secretion from pancreatic beta cells in response to nutrient intake Enhanced insulin sensitivity in peripheral tissues Modulation of adipocyte lipolysis with potential effects on fat distribution Reduced inflammatory signaling in adipose tissue Structural studies using cryo-electron microscopy revealed that GLP3 peptide forms specific interactions with the GIP receptors extracellular loop 1, a region exhibiting receptor-specific conformational flexibility that contributes to the peptides preferential GIP receptor activation[5]
Common side effects include: Nausea and vomiting Diarrhoea or constipation Reduced appetite (which is also a therapeutic effect) Injection site reactions (redness, bruising, or mild discomfort) These effects are typically mild to moderate and tend to resolve as the body adjusts to the medication
Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al
The reason I say this is because with Triumph-1 Eli Lilly only had the raw trial data for a couple weeks, so they scrambled to pull out the stuff thats relevant to a conference such as this meaning any deeper exploration on the liver and kidney were left out
